Omvoh shows 63.5% durable disease clearance in ulcerative colitis patients after 4 years of treatment

New data from Eli Lilly reveal that 63.5% of ulcerative colitis patients treated with Omvoh maintained disease clearance after four years of continuous treatment. Disease clearance means simultaneous symptom relief, and endoscopic and histologic remission, a high clinical standard linked to fewer hospitalizations and surgeries. This is the first IL-23p19 inhibitor to demonstrate such long-term durable remission, potentially changing the disease's long-term course. Eli Lilly is also exploring combination therapies and pediatric trials to further improve outcomes.